Mackie Research has initiated coverage on Medicure Inc. (TSXV: MPH)

Name: Mackie Research has initiated coverage on Medicure Inc. (TSXV: MPH)
Uploaded: 2014-10-03T18:55:37+00:00
Duration: 168 s
Description: Analyst Andre Uddin gives the company a speculative buy recommendation and 12-month target of $2.80, a premium of 33% to the $2.10 price on September 26th, the day the report was issued. Medicure is a commercial-stage specialty pharmaceutical company specialized in cardiology.

47 просмотров 03.10.2014 00:02:48

Описание

Analyst Andre Uddin gives the company a speculative buy recommendation and 12-month target of $2.80, a premium of 33% to the $2.10 price on September 26th, the day the report was issued. Medicure is a commercial-stage specialty pharmaceutical company specialized in cardiology.

Недавно искали

53024 20160208 20231007 60610 170228 0021 10131363 93210 193825 1663 1237 2012 2002 2000 2011 2016 2003 1981 2017 2007 2001 2004 2018 2014 2005 1978 1985 2015 1963 1998 2008 2020 2013 2500 0845 1972 1983 2006 0885 1950 2009 1971 80920 1996 2200 2019 1992 11624 80915 2102 0141 1980 0878 1976 0909 1994 1002 1000 4036 0773 1999 1200 1967 20109 4262 1975 2010 75005 6476 355000 2160 7301 16151 0505 5282 1100 75014 1500 06320 9540 032312 170111 170412 161229 31072010 071012 050910 090722 090830 230210 131101 92300 300909 132706 6435829 090622 170601 сеад 191124 211210

Mackie Research has initiated coverage on Medicure Inc. (TSXV: MPH)

Описание

Комментарии

Недавно искали